Category: Angela Christiano

2017: A Look Ahead

I’ve got a good feeling about 2017… For the past several years we have been pacified by the news of a research study or startup company working on a treatment that grows hair. Ultimately, we would prefer the… Read More

HairClone Growing, Aclaris IND: Weekly Thoughts 11/9/16

Hello everyone, and welcome to another edition of Weekly Thoughts. It has been a little while since my last check in with you all. You can chalk it up to a busy schedule and the fact that there… Read More

L’Oreal 3D Printing, Hope for AA, Stem Cell Transplants: Weekly Thoughts 10/10/16

Hello everyone, and welcome to another edition of Weekly Thoughts. Things have been really busy in the hair world as of late, new companies are popping up all the time and companies that we have known about are… Read More

Rapunzel Still Growing, Histogen Talk, Ultimate Guide Update: Weekly Thoughts 8/17/16

Hello Everyone, Welcome to another edition of Weekly Thoughts. This week’s news consists of an update on Christiano’s cellular hair growth startup Rapunzel, some interesting tidbits on Histogen, and updates being made to the Ultimate Guide to Hair… Read More

Vixen Pharmaceuticals Acquired By Aclaris Therapeutics

Well you guys asked for it, right? An established pharmaceutical company has acquired the rights to Angela Christiano’s hair growth research involving JAK inhibitors. Aclaris Therapeutics has entered into an agreement with Vixen to acquire all of the… Read More

JAK Research, Shiseido Research: Weekly Thoughts 1/12/16

Hello Everybody, Welcome to another edition of Weekly Thoughts. This weeks’s round-up includes new tidbits from Angela Christiano, Brian Urlacher’s hair transplant, Shiseido’s plethora of reseachers, and an Ultimate Guide update.

Samumed Results, Theracell Product: Weekly Thoughts 12/8/15

The Holiday season is in full swing, and there is a lot to be happy about in the world of hair regeneration. For starters, Histogen and Replicel should both be available within about two years time. See previous… Read More